Genomic profiling of breast cancer in Sweden
Official title: SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative
Run by Lund University · NCT02306096 · Data updated 2026-11-12
This study looks at the genetic makeup of breast cancer in over 20,000 patients in Sweden to see how it can help tailor treatments and improve outcomes for those affected.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Lund University Academic / other |
| Locations | 10 sites (Borås and 9 other locations) |
| Status | Recruiting |
| Started | August 2010 |
| Main results expected | August 2031 |
| Study ends | August 2031 |
| Registry record updated | August 27, 2026 |
| Trial ID | NCT02306096 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a suspicion or confirmed diagnosis of primary breast cancer who can provide informed consent.
✕Probably not a fit
Patients without a confirmed diagnosis of breast cancer or those who do not provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the genomic profiles of breast cancer through whole transcriptome RNA-sequencing in a prospective, population-based manner. It aims to analyze gene expression, mutational profiles, and transcript isoform-level data in relation to patient information and clinical outcomes. The goal is to develop new molecular diagnostic assays that can personalize treatment and improve patient outcomes. The study has enrolled over 20,000 patients, representing a significant portion of breast cancer cases in Sweden.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for breast cancer patients.
How similar studies have gone: Other studies utilizing genomic profiling in cancer have shown promise, indicating that this approach may yield valuable insights and advancements in breast cancer treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspicion or confirmed diagnosis of primary breast cancer * signed informed consent Exclusion Criteria: * lack of signed informed consent
Where it's running
-
Södra Älvsborg Hospital
Borås, Sweden Recruiting -
Helsingborg Hospital
Helsingborg, Sweden Recruiting -
Blekinge County Hospital
Karlskrona, Sweden Recruiting -
Central Hospital Kristianstad
Kristianstad, Sweden Recruiting -
Skåne University Hospital
Lund, Sweden Recruiting -
Skåne University Hospital
Malmö, Sweden Recruiting
Show 4 more locations
-
Uppsala University Hospital
Uppsala, Sweden Recruiting -
Central Hospital Växjö
Vaxjo, Sweden Recruiting -
Hallands Hospital Halmstad
Halmstad, Sweden Suspended -
Kirurgiska kliniken
Jönköping, Sweden Suspended
Study contacts
- Principal investigator: Christer Larsson, PhD — Lund University
- Study coordinator: Åke Borg, PhD
- Email: ake.borg@med.lu.se
- Phone: +46-46-2752552
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making
This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.
-
Slow Jogging for Breast Cancer Survivors
This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.